Natera, Inc. (NASDAQ:NTRA) Holdings Decreased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lessened its stake in Natera, Inc. (NASDAQ:NTRA) by 45.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 51,701 shares of the medical research company’s stock after selling 42,869 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Natera were worth $8,198,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Creative Planning increased its stake in shares of Natera by 28.3% during the second quarter. Creative Planning now owns 4,929 shares of the medical research company’s stock valued at $534,000 after acquiring an additional 1,087 shares during the period. Sanctuary Advisors LLC acquired a new stake in shares of Natera in the second quarter valued at $380,000. GAMMA Investing LLC boosted its stake in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares in the last quarter. CWM LLC grew its holdings in Natera by 119.5% during the third quarter. CWM LLC now owns 15,441 shares of the medical research company’s stock worth $1,960,000 after acquiring an additional 8,406 shares during the period. Finally, Exchange Traded Concepts LLC raised its position in Natera by 30.5% in the third quarter. Exchange Traded Concepts LLC now owns 12,064 shares of the medical research company’s stock worth $1,532,000 after acquiring an additional 2,821 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Trading Down 1.3 %

Natera stock opened at $172.82 on Friday. The company’s fifty day simple moving average is $167.56 and its 200-day simple moving average is $140.02. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12 month low of $67.33 and a 12 month high of $183.00. The stock has a market cap of $22.82 billion, a P/E ratio of -98.19 and a beta of 1.66.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.95) EPS. As a group, sell-side analysts forecast that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on NTRA shares. Barclays started coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price objective on the stock. Guggenheim upped their price target on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Canaccord Genuity Group upped their target price on Natera from $165.00 to $180.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Finally, Craig Hallum boosted their price objective on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $165.88.

Insider Activity

In related news, insider John Fesko sold 663 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares in the company, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Roelof Botha sold 87,473 shares of Natera stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the completion of the transaction, the director now directly owns 1,224,787 shares in the company, valued at approximately $207,135,977.44. This represents a 6.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 312,394 shares of company stock worth $52,333,520. 7.60% of the stock is owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.